Effects of Micronized Trans-resveratrol Treatment on Polycystic Ovary Syndrome (PCOS) Patients

Not Applicable

• Conditions: Polycystic Ovary Syndrome (PCOS)
• Interventions: Dietary Supplement: Placebo; Dietary Supplement: Micronized trans-resveratrol

• Registration Number: NCT01720459
• Lead Sponsor: Poznan University of Medical Sciences

Brief Summary

The purpose of this study is to determine whether micronized trans-resveratrol improves clinical (excessive hair, menstrual cycle), endocrine (androgens)and metabolic (lipids, markers of systemic inflammation) in women with polycystic ovary syndrome (PCOS).

Detailed Description

Not available

Study Timeline

• Status Verified: 2012-10
• Study First Submitted: 2012-10-31
• Study First Submitted QC: 2012-11-01
• Last Update Submitted: 2012-11-01
• Study First Posted: 2012-11-02
• Last Update Posted: 2012-11-02
• Study Start: 2012-12
• Primary Completion: 2013-12
• Study Completion: 2014-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 40

Inclusion Criteria

• PCO - Androgen Excess Society criteria: hyperandrogenism (hirsutism) / hyperandrogenemia (testosterone >70ng/dl) and/or oligomenorrhea (<8 spontaneous menses per year) and/or polycystic ovarian morphology on ultrasound
• Normal prolactin, TSH, 17-OH progesterone
• No evidence of androgen producing malignancy, Cushing's syndrome or acromegaly
• Age 18-40

Exclusion Criteria

• Use of oral contraceptives and/or other steroid hormones 3 months prior to the study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	-
Micronized trans-resveratrol	Micronized trans-resveratrol	Micronized trans-resveratrol

Primary Outcome Measures

Name	Time	Method
testosterone serum concentration	3 month therapy

Trial Locations

Locations (1)

Poznan University of Medical Sciences; 🇵🇱 Poznan, Poland